Positive phase II results for RenaMed therapy

The study of 58 patients found that RenaMed’s therapy increased survival rate by 72% at 28 days, a trend for improved survival sustained through 90 and 180 days. The preliminary results were presented at the 38th annual meeting of the American Society of Nephrology.

While dialysis and hemofiltration replace the waste and fluid balance functions of the kidney, these processes do not replace the kidney’s essential metabolic and endocrine functions. Bio-replacement therapy is designed to replace these additional, essential kidney functions during a critical phase of acute renal failure (ARF) and to work in conjunction with existing hemofiltration systems to provide comprehensive kidney function support.

“Despite improving methods for delivering dialysis, mortality rates for patients with ARF have remained unacceptably high for the past 30 years,” said Dr James Tumlin, associate professor of medicine at Emory University and a principal investigator in the study. “If this difference (in mortality rate) is supported in subsequent studies, the use of “biologics” along side conventional forms of dialysis will be a major advance in the treatment of ARF.”